Cogstate (CGS) H2 2024 earnings summary

Executive summary

• Group revenue increased 7% year-over-year to $43.4m, driven by 9% growth in clinical trials revenue, despite a 21% decline in new clinical trial sales contracts and a decrease in healthcare revenue due to the Eisai agreement renegotiation.

• Profit before tax more than doubled to AUD 7.1 million (up 135%), with EBIT up 196% to $6.5m, reflecting strong operational leverage and cost management.

• The company executed AUD 27 million in clinical trial sales contracts, with AUD 14 million from non-Alzheimer's indications, representing 60% growth in that segment.

• The renegotiation of the Eisai license agreement returned IP control to the company, enabling new commercial opportunities and community-focused technology deployment.

• The share buyback program, which used $5.5m in FY24, has been suspended to preserve capital for potential strategic acquisitions.

Financial highlights

• Clinical trials gross margin improved by six points, turning a AUD 3.3 million revenue increase into a AUD 4 million gross profit increase, with overall gross profit up 18% to $24.6m.

• Operating expenses declined 4% year-over-year, despite higher bonus accruals.

• Operating cash flow rose to AUD 5.8 million from AUD 0.7 million, with net cash at AUD 29.4 million at year-end.

• EBIT reached AUD 6.5 million, up significantly from the prior year.

• Future contracted revenue stands at AUD 110.9 million, down 16% year-over-year, with $33.6m expected to be recognized in FY25.

Outlook and guidance

• Management expects revenue and profit growth in FY2025, supported by a strong start with AUD 9.3 million in new clinical trial contracts in the first seven weeks.

• No specific financial guidance provided; future revenue recognition depends on further contract execution.

• The company targets EBIT margins in the 20%+ range, with technology investments expected to support further margin expansion.